Recent studies into axSpA treatment focus on how to ease inflammatory symptoms and boost health-related quality of life.
Sustained clinically important improvement associated with ixekizumab q4 weeks was maintained in patients through 3 years, per the results of the COAST program.
Targeting IL-17F plus IL-17A with bimekizumab may be effective in treating a broad range of axSpA presentations.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that ravages the axial skeleton and sacroiliac joints. It involves two subtypes: radiographic axSpA (r-axSpA) and nonradiographic axSpA (nr-axSpA). As their names imply, these subtypes differ based on the presence or absence of frank radiographic sacroiliitis on X-ray.
The goal of treatment for axSpA is to maximize long-term health-related quality of life via the control of inflammatory symptoms, the prevention of progressive structural damage, and the preservation or normalization of social function.
As of late, there have been a number of important studies regarding treatments for axSpA. Here are three of the most significant.
Insight into longer-term use of ixekizumab
Publishing in Journal of Rheumatology, investigators reported on the safety and efficacy of ixekizumab from the COAST program through a study duration of 3 years.
Ixekizumab is a high-affinity monoclonal antibody that targets interleukin (IL)-17A. In the COAST program, it previously demonstrated efficacy at week 16, which held at 2 years in patients with r-axSpA and nr-axSpA. In addition, no new safety signals emerged.Related: Disease activity measures to improve outcomes in axSpA
Ixekizumab’s 3-year safety profile in the COAST program aligned with the previously established results. Sustained improvement of disease activity and clinically important improvement (CII) with use of ixekizumab q4 weeks was maintained in patients through 3 years.
"Determining the safety profile of a biologic from multiple studies and long-term extension studies is of the utmost importance for patients receiving longstanding treatment."
— Authors, Journal of Rheumatology
Exploring re-treatment with etanercept
The RE-EMBARK study assessed etanercept withdrawal and re-treatment in patients with nr-axSpA who had already achieved inactive disease.
Requested by the European Medicines Agency (EMA), RE-EMBARK is a postapproval study examining the frequency of flares following etanercept withdrawal in patients with inactive disease, as well as the efficacy and safety of re-treatment following such flares. The post-hoc analysis examined predictors of the maintenance of inactive disease after ETN withdrawal, as well as predictors of re-achieving inactive disease after flare-ups and etanercept re-treatment.
Following the discontinuation of etanercept, approximately 25% of patients maintained inactive disease for 40 weeks. Baseline predictors of response maintenance following etanercept withdrawal included both the lack of MRI sacroiliitis and the presence of elevated levels of high-sensitivity C-reactive protein (hs-CRP).
“An early, aggressive, treat-to-target approach is recommended in axSpA to improve outcomes. Another benefit of this strategy may determine whether some patients can maintain remission after expensive biologic treatment is discontinued,” wrote the study authors.
“Results from RE-EMBARK suggest that treatment goals can be achieved even after ETN [etanercept] discontinuation in some (ie, 25%) patients. Studies of other TNFi medications—infliximab (IFX), adalimumab (ADA), certolizumab pegol (CZP), and ixekizumab—demonstrated sustained responses in a portion of patients with axSpA following treatment withdrawal. Moreover, many patients in remission and who flared following withdrawal regained inactive disease status after retreatment,” the authors added.
The RE-EMBARK results provide evidence that, in a monitory yet substantial number of patients, stopping biologic therapy after remission is achieved may result in continued remission in the absence of therapy.
Leveraging bimekizumab across the axSpA spectrum
New treatments are an unmet need in axSpA, as it is a complex disease with widely heterogeneous clinical presentations. BE MOBILE 1 and BE MOBILE 2—which involve nr-axSpA and r-axSpA patients, respectively—are double-blind phase 3 trials that examine the efficacy and safety of bimekizumab. This monoclonal antibody is a novel dual IL-17A/IL-17F inhibitor and can be used for a gamut of axSpA symptomatic presentations.Related: Unmet need: What precision medicine can do for rheumatology
Compared with the placebo arm, dual inhibition of IL-17A and IL-17F with bimekizumab yielded swift improvements in efficacy outcomes, as well as being well tolerated in nr-axSpA and r-axSpA patients.
Improvements were observed in the Ankylosing Spondylitis Disease Activity Score (ASDAS) states, and objective measures of inflammation such as hs-CRP and MRI of the sacroiliac joints and spines were also ameliorated.Related: Interpreting DAS28-CRP: A marker for clinical improvement in RA?
“The positive findings from the BE MOBILE 1 study provide clear evidence supporting bimekizumab in the treatment of nr-axSpA, and suggest that targeting IL-17F in addition to IL-17A may be a promising treatment approach for this painful, chronic rheumatic condition that often starts in young adulthood,” said rheumatologist Atul Deodhar, MD, one of the study investigators, to the Spondylitis Association of America (SAA).
What this means for you
Various new treatments show promise in the treatment of axSpA. These include ixekizumab, with sustained efficacy and safety at 3 years’ study duration; etanercept, associated with maintained remission following discontinuation; and bimekizumab, showing safety and efficacy across a large swath of the total axSpA patient population. These studies warrant further attention from practicing rheumatologists, as the results could translate to improved outcomes and symptom relief among people who struggle with this debilitating condition.